Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres

image

SIROS Control your Y-90 delivery with confidence. (Credit: Business Wire.)

Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS™, an innovative system for the delivery of SIR-Spheres® Y-90 resin microspheres.

SIROS™ offers a visual, intuitive and versatile option for interventional radiologists to deliver SIR-Spheres® to patients with liver cancer. With the system’s visually controlled administration, physicians can determine and adjust the precise quantity and speed of SIR-Spheres® microspheres delivery. Additionally, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.

SIROS™’ intuitive design features a peel-and-place tubing set, a proprietary needleless D-Vial specifically designed to suspend SIR-Spheres® into a vortex that may allow for a more even distribution, and a locking cover to safely secure the microspheres during delivery. A three-step setup further provides quick and simple administration and disposal.

“SIROS™ brings world-class expertise and innovation together to provide interventional radiologists with the support and technology they need to treat patients with liver cancer,” said Kevin R. Smith, Chief Executive Officer of Sirtex. “As established leaders in the industry for more than 20 years, we are pleased to add SIROS™ to our expanding portfolio of technology designed to advance patient care.”

Source: Company Press Release